ES3061325T3 - Chimeric proteins for use in the treatment of central nervous system disorders - Google Patents

Chimeric proteins for use in the treatment of central nervous system disorders

Info

Publication number
ES3061325T3
ES3061325T3 ES21849618T ES21849618T ES3061325T3 ES 3061325 T3 ES3061325 T3 ES 3061325T3 ES 21849618 T ES21849618 T ES 21849618T ES 21849618 T ES21849618 T ES 21849618T ES 3061325 T3 ES3061325 T3 ES 3061325T3
Authority
ES
Spain
Prior art keywords
chimeric proteins
treatment
nervous system
central nervous
system disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21849618T
Other languages
English (en)
Spanish (es)
Inventor
Samuel J Pfaff
Yan Zhang
Kristopher M Kuchenbecker
Lakhmir S Chawla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silver Creek Pharmaceuticals Inc
Original Assignee
Silver Creek Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silver Creek Pharmaceuticals Inc filed Critical Silver Creek Pharmaceuticals Inc
Application granted granted Critical
Publication of ES3061325T3 publication Critical patent/ES3061325T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES21849618T 2020-07-30 2021-07-30 Chimeric proteins for use in the treatment of central nervous system disorders Active ES3061325T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063058888P 2020-07-30 2020-07-30
PCT/US2021/044019 WO2022026902A2 (en) 2020-07-30 2021-07-30 Chimeric proteins and methods of use for treatment of central nervous system disorders

Publications (1)

Publication Number Publication Date
ES3061325T3 true ES3061325T3 (en) 2026-04-01

Family

ID=80002512

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21849618T Active ES3061325T3 (en) 2020-07-30 2021-07-30 Chimeric proteins for use in the treatment of central nervous system disorders

Country Status (8)

Country Link
US (2) US20220031812A1 (https=)
EP (1) EP4188410B1 (https=)
JP (1) JP2023537318A (https=)
CN (1) CN116917482A (https=)
AU (1) AU2021319203A1 (https=)
CA (1) CA3187734A1 (https=)
ES (1) ES3061325T3 (https=)
WO (1) WO2022026902A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023512423A (ja) 2019-12-24 2023-03-27 ジュベナ・セラピューティクス・インコーポレイテッド 再生性ポリペプチドおよびその使用
KR20240029031A (ko) 2021-06-21 2024-03-05 쥬베나 테라퓨틱스, 인크. 재생 폴리펩티드 및 이의 용도
WO2023159067A2 (en) * 2022-02-15 2023-08-24 Silver Creek Pharmaceuticals, Inc. Chimeric proteins for treatment of acute radiation syndrome
EP4658295A2 (en) * 2023-02-02 2025-12-10 Silver Creek Pharmaceuticals, Inc. Methods of treatment using igf-1 chimeric proteins
CN116549667B (zh) * 2023-05-29 2024-02-09 四川普锐特药业有限公司 一种pas修饰的脂质纳米粒、包含其的药物制剂，及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
JP5577098B2 (ja) * 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
CN105524176B (zh) * 2010-05-21 2021-03-19 银溪制药股份有限公司 双特异性融合蛋白
BR112012029611A2 (pt) 2010-05-21 2017-07-25 Merrimack Pharmaceuticals Inc proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico
DK2699598T3 (en) * 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
CN115960249A (zh) 2015-10-02 2023-04-14 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质

Also Published As

Publication number Publication date
EP4188410A2 (en) 2023-06-07
EP4188410B1 (en) 2025-11-05
AU2021319203A1 (en) 2023-03-02
CN116917482A (zh) 2023-10-20
JP2023537318A (ja) 2023-08-31
US20260041738A1 (en) 2026-02-12
CA3187734A1 (en) 2022-02-03
WO2022026902A2 (en) 2022-02-03
US20220031812A1 (en) 2022-02-03
WO2022026902A3 (en) 2022-03-10
EP4188410A4 (en) 2024-10-02

Similar Documents

Publication Publication Date Title
ES3061325T3 (en) Chimeric proteins for use in the treatment of central nervous system disorders
ECSP22029193A (es) Aminas bicíclicas como inhibidoras de la cdk2
CL2018003438A1 (es) Anticuerpos a la alfa-sinucleína y usos de los mismos.
CO2021005987A2 (es) Compuestos de anillo fusionado
CO2021003036A2 (es) Compuestos de anillo fusionado
CL2021001308A1 (es) Derivados de bis-octahidrofenantreno carboxamida y conjugados de proteína de los mismos para su uso como agonistas de lxr.
CL2019001129A1 (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y.
MX2018010415A (es) Composiciones y metodos para inmunoterapia de grupo de diferenciacion 20 (cd20).
UY38476A (es) Inhibidores de arg1 y/o arg2
JOP20170170A1 (ar) صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
ES3060595T3 (en) Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
CL2017000111A1 (es) Moléculas con especificidad para cd45 y cd79
DOP2025000199A (es) Agonistas heterocíclicos de glp-1
PE20210452A1 (es) Inhibidores de la arginasa
MX2018005070A (es) Composición para el tratamiento de cáncer con expresión del igf-1r.
ES3060591T3 (en) Modified polymerases for improved incorporation of nucleotide analogues
CL2021001593A1 (es) Tubulisinas y conjugados de proteína-tubulisina
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
MX2018009952A (es) Moduladores alostericos positivos del receptor de acetilcolina muscarinico m1.
MX2021004925A (es) Variantes de adn-polimerasa modificadas.
CL2019002583A1 (es) Inhibidores duales de magl y faah.
DOP2018000179A (es) Piperidinas sustituidas con halo como moduladores del receptor de orexina
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.